- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05647967
Features of Regional Perfusion of Lung Consolidation
December 8, 2022 updated by: Peking Union Medical College Hospital
Evaluation of Regional Perfusion of Lung Consolidation Upon Lung Ultrasonography
The aim of this study is to evaluate the potential usefulness of lung ultrasound to assess the size and perfusion of consolidation and explore their relationships with clinical outcome.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Lung consolidation is one of the most causes of hypoxia in intensive care unit(ICU) settings.
A quantitative measurement of consolidation would be extremely benefit for the clinical management in hypoxemia, both as an index of severity and to predict outcomes.In order to quantify the lung consolidation and its effect on clinical outcomes, a simple and quantitative scoring system of the size and perfusion of lung consolidation was proposed by lung ultrasound.
Subjects with respiratory failure and lung consolidation proved by chest imaging underwent lung ultrasound examination.
The size of consolidation and the richness of blood flow was computed upon lung ultrasound.
The sensitivity, specificity and accuracy of the scoring system were calculated and compared to evaluate the diagnostic efficacy.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Na Wang, MD
- Phone Number: 17810258960
- Email: wangna_pumch2017@163.com
Study Contact Backup
- Name: Huaiwu He, MD
- Phone Number: 010-69152300
- Email: timuhhw@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Na Wang, MD
- Phone Number: 17810258960
- Email: wangna_pumch2017@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 86 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study population consisted of adult(>18yr) patients admitted to the ICU.
Patients presented with acute respiratory failure and pulmonary consolidation by chest imaging (lung ultrasound, X ray or CT scan) were eligible for inclusion.
Acute respiratory failure was defined by at least one of the following criteria: PaO2/FiO2<300mmHg, breathing frequencies>30 breath/min, and could involve many potential causes of hypoxemia (e.g., sepsis, atelectasis, pneumonia, acute exacerbation of chronic lung disease).
Description
Inclusion criteria:
- Admission to ICU( 18yr<age<90yr);
- Patients presented with acute respiratory failure;
- Pulmonary consolidation by chest imaging (lung ultrasound, X ray or CT scan).
Exclusion criteria:
- Hemodynamic instability (i.e., severe hypotension with systolic arterial pressure<60mmHg despite fluid expansion and vasoactive support; systolic arterial pressure>180mmHg; uncontrolled cardiac arrhythmias);
- Severe thoracic trauma;
- Coronavirus disease 2019;
- Pulmonary artery hypertension and pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
the consolidation perfusion/the consolidation size
Patients with respiratory failure and lung consolidation proved by chest imaging underwent lung ultrasound to evaluate the regional perfusion and the size of consolidation.
|
Each patient underwent ultrasound after admission of ICU.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
consolidation area index
Time Frame: through study completion, an average of 2 year
|
The volume of consolidation was measured by consolidation area index (CAI) which is calculated from two-dimensional measures, namely the product of the core distance (from the bottom to the top of the screen) and the longitudinal distance (from the left to the right of the screen).
|
through study completion, an average of 2 year
|
|
blood flow score
Time Frame: through study completion, an average of 2 year
|
A semi-quantified scoring system based on the richness of flow signals was established.
It identifies four progressive steps of blood signals, each corresponding to a score: no pulsatile blood flow-score 0; sparse dot-like blood flow-score 1; pronounced curvilinear vascularity-score 2; tree-like vascularity-score 3.
|
through study completion, an average of 2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Huaiwu He, MD, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
January 31, 2024
Study Registration Dates
First Submitted
November 29, 2022
First Submitted That Met QC Criteria
December 8, 2022
First Posted (Estimate)
December 13, 2022
Study Record Updates
Last Update Posted (Estimate)
December 13, 2022
Last Update Submitted That Met QC Criteria
December 8, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I-22PJ140
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ultrasound Therapy; Complications
-
Assiut UniversityRecruitingUltrasound Therapy; ComplicationsEgypt
-
National Cancer Institute, EgyptCompletedUltrasound Therapy; ComplicationsEgypt
-
Ataturk UniversityCompletedUltrasound Therapy; ComplicationsTurkey
-
Rongqin ZhengNot yet recruiting
-
Tongji HospitalCompletedUltrasound Therapy; ComplicationsChina
-
National Taiwan University HospitalCompletedUltrasound Therapy; ComplicationsTaiwan
-
Omer KaracaBaskent UniversityCompletedUltrasound Therapy; ComplicationsTurkey
-
Assiut UniversityNot yet recruitingUltrasound Therapy; Complications
-
Cairo UniversityNot yet recruitingUltrasound Therapy; Complications
-
Carilion ClinicRecruitingUltrasound Therapy; ComplicationsUnited States
Clinical Trials on Ultrasound
-
Ahram Canadian UniversityCompletedCarpal Tunnel Syndrome | Median Neuropathy, Carpal TunnelEgypt
-
Eskisehir Osmangazi UniversityCompletedCarpal Tunnel Syndrome
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Cairo UniversityUnknown
-
Ohio State University Comprehensive Cancer CenterWithdrawn
-
Oregon Health and Science UniversityRecruiting
-
Yale UniversityCompletedPneumonia | Pulmonary Edema | DyspneaUnited States
-
Odense University HospitalEnrolling by invitationThoracic Ultrasound | Fibrosing Interstitial Lung DiseasesDenmark
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedShoulder Impingement Syndrome | Shoulder PainTurkey
-
John PelleritoGeneral ElectricActive, not recruiting